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Abstract
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United
States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or
small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved
efficacy of single-agent ibrutinib over ofatumumab in patients with relapsed/refractory
CLL/SLL, including those with high-risk features. Here we report the final analysis from
RESONATE with median follow-up on study of 65.3 months (range, 0.3-71.6) in the
ibrutinib arm. Median progression-free survival (PFS) remained significantly longer for
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patients randomized to ibrutinib vs ofatumumab (44.1 vs 8.1 months; hazard ratio [HR]:
0.148; 95% confidence interval [CI]: 0.113-0.196; P˂.001). The PFS benefit with ibrutinib
vs ofatumumab was preserved in the genomic high-risk population with del(17p), TP53
mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR:
0.110; 95% CI: 0.080-0.152), which represented 82% of patients. Overall response rate
with ibrutinib was 91% (complete response/complete response with incomplete bone
marrow recovery, 11%). Overall survival, censored for crossover, was better with ibrutinib
than ofatumumab (HR: 0.639; 95% CI: 0.418-0.975). With up to 71 months (median
41 months) of ibrutinib therapy, the safety profile remained consistent with prior reports;
cumulatively, all-grade (grade ≥3) hypertension and atrial fibrillation occurred in 21% (9%)
and 12% (6%) of patients, respectively. Only 16% discontinued ibrutinib because of
adverse events (AEs). These long-term results confirm the robust efficacy of ibrutinib in
relapsed/refractory CLL/SLL irrespective of high-risk clinical or genomic features, with no
unexpected AEs. This trial is registered at www.clinicaltrials.gov (NCT01578707).
1 | INTRODUCTION
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma
(SLL) are heterogenous diseases with outcomes that are affected
by clinical status and genetic aberrations.1 Patients with relapsed
CLL/SLL and known high-risk factors, such as 17p deletion (del[17p]),
TP53 aberrations (deletion/mutation), 11q deletion (del[11q]), or
unmutated immunoglobulin heavy chain variable region (IGHV) gene,
have a poor prognosis, and recent International Workshop on Chronic
Lymphocytic Leukemia (IWCLL) guideline updates recommend testing
for these high-risk factors to aid in treatment decisions.2-6 Chemo-
immunotherapy has been at the forefront of treatment of CLL/SLL in
the past decade, resulting in improved progression-free survival (PFS)
and overall survival (OS) outcomes for untreated patients requiring
therapy.7-11 Additionally, treatment of relapsed CLL/SLL with combi-
nation chemoimmunotherapy resulted in modest improvements in
PFS and, in some cases, OS.12-14 In the past, however, once patients
became refractory to chemoimmunotherapy, especially those with
early relapse or high-risk genomic features, treatment options were
limited and survival time was short.
The introduction of targeted therapy to the armamentarium of
CLL/SLL therapy has dramatically improved treatment outcomes in
patients refractory to chemoimmunotherapy. Ibrutinib, a first-in-class,
once-daily, covalent inhibitor of Bruton's tyrosine kinase (BTK; a B-cell
receptor signaling kinase expressed by various hematopoietic cells,
B-cell lymphomas, and leukemias), was one such therapy introduced
in this relapsed and refractory CLL/SLL population that has since
revolutionized therapy.15 RESONATE was the first multicenter,
open-label, randomized phase 3 study that compared ibrutinib to
ofatumumab treatment outcomes in previously treated patients with
CLL/SLL, leading to full FDA approval of ibrutinib (after prior acceler-
ated approval), including in patients with del(17p). The analysis from
the first report of this trial demonstrated that ibrutinib significantly
improved PFS, OS, and overall response rates (ORR) compared with
ofatumumab and was generally well tolerated.16 RESONATE was also
the first randomized trial that identified adverse events (AEs) associated
with ibrutinib, such as atrial fibrillation and bruising, that have been
followed long-term with BTK inhibitors. Herein, we report the final long-
term follow-up efficacy and safety results of this landmark study, includ-
ing analyses of subgroups with high-risk genomic features.
2 | METHODS
2.1 | Patients
Detailed eligibility criteria have been previously published.16 Briefly,
patients with active relapsed/refractory CLL or SLL with measurable
nodal disease by computed tomography (CT) who failed ≥1 prior line of
therapy and met the International Workshop on Chronic Lymphocytic
Leukemia (IWCLL) 200817 guidelines for requiring therapy, but were not
candidates for purine analog therapy (see Supplementary Methods), were
eligible for inclusion in the study. All patients provided written informed
consent. The study was approved by the institutional review board or
independent ethics committee at each participating institution and was
conducted in accordance with the Declaration of Helsinki and Interna-
tional Conference on Harmonisation Guideline for Good Clinical Practice.
The study was sponsored by Pharmacyclics LLC, an AbbVie Company,
and Janssen Research and Development LLC.
2.2 | Study Design
RESONATE was a randomized, multicenter, open-label, phase 3 study
that evaluated the efficacy and safety of ibrutinib compared with
ofatumumab in previously treated patients with relapsed or refractory
CLL/SLL (clinicaltrials.gov number NCT01578707). Enrollment was
from June 2012 to April 2013. Patients were randomly assigned 1:1
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to receive either oral ibrutinib 420 mg once daily (until disease pro-
gression or unacceptable toxicity) or intravenous ofatumumab for up
to 24 weeks at an initial dose of 300 mg at week one, followed by a
dose of 2000 mg weekly for seven weeks and then every four weeks
for 16 weeks. Stratification was by purine analog refractory status
(defined as no response to or relapse within 12 months of last dose of
purine analog) and presence or absence of del(17p). Based on durable
responses in the ongoing pivotal phase 2 study PCYC-1102,18 a pro-
tocol amendment was instituted in August 2013 to allow patients on
the ofatumumab arm to cross over to receive ibrutinib. Following
study closure, eligible patients could continue to receive ibrutinib
treatment in a long-term extension study (PCYC-1145-LT;
clinicaltrials.gov number NCT03229200).
2.3 | Assessments
PFS per investigator assessment was based on IWCLL 2008 criteria,17 with
the2012 clarification that treatment-related lymphocytosiswas not consid-
ered progressive disease (PD) if in the setting of improvement in other dis-
ease parameters. Other endpoints were ORR per investigator assessment
(defined as the proportion of patients who achieved complete response
[CR], CR with incomplete bone marrow recovery [CRi], nodular partial
response, partial response, or partial response with lymphocytosis),17 OS,
and safety. Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F) was a secondary endpoint; other patient-reported outcomes
were exploratory endpoints. Methods for monitoring patients during
follow-up have been described and were continued through long-term
follow-up. Details of assessments, including patient-reported outcomes and
cytogenetics, are provided in the SupplementaryMethods.
2.4 | Statistical methods
Long-term efficacy, including PFS, OS, and ORR, were assessed in the
intent-to-treat population. PFS and ORR were based on investigator
assessment (independent review committee assessments were per-
formed only for the primary analysis).16 PFS and OS (with and without
censoring at crossover for ofatumumab patients) were analyzed using
Kaplan-Meier methodology and hazard ratio (HR) was estimated using
Cox regression model. In addition, the rank-preserving structural
failure time (RPSFT) randomization-based model was employed to
estimate the OS HR using counterfactual survival times that would
have been observed in the absence of the extensive crossover.
Ofatumumab treatment was completed at the time of the primary
analysis and reported in the previous report. Long-term safety was
summarized by yearly interval for ibrutinib patients.
2.5 | Data sharing statement
Requests for access to individual participant data from clinical studies
conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted
through Yale Open Data Access (YODA) Project site at http://yoda.
yale.edu.
3 | RESULTS
3.1 | Patient features
Baseline characteristics of patients randomized to ibrutinib (n = 195)
or ofatumumab (n = 196) are shown in Table S1.19 Similar proportions
of patients in the ibrutinib and ofatumumab arms had high-risk fea-
tures, including del(17p) (32% and 33%, respectively), mutated TP53
(51% and 46%, respectively), del(11q) (33% and 31%, respectively),
unmutated IGHV (73% and 63%, respectively), and complex karyotype
(25% and 22%, respectively) (Table S1). The majority of patients in
both the ibrutinib and ofatumumab arms (86% and 79%, respectively)
comprised the high-risk population, defined as having any of the fol-
lowing: del(17p), TP53 mutation, del(11q), and/or unmutated IGHV
status.
The final analysis was performed upon study closure. Median follow-
up on the study of patients initially assigned to ibrutinib was 65.3 months
(range: 0.3−71.6), and median duration of ibrutinib therapy was
TABLE 1 Patient disposition and treatment exposure during
study treatment
Parameter, n (%)
Ibrutinib
(n = 195)
Ofatumumab
(n = 196)
Duration of treatment, months,
median (range)
41.0 (0.2-71.1) 5.3 (0.0-9.0)
Disposition of study treatment
Did not receive study drug 0 5 (2.6)
Completed treatment
(ofatumumab arm only)
N/A 120 (61.2)
Discontinued 195 (100.0) 71 (36.2)
Progressive disease 72 (36.9) 36 (18.4)
Study terminated by
sponsor
43 (22.1) 0
Adverse event 32 (16.4) 7 (3.6)
Patient withdrawal 15 (7.7) 6 (3.1)
Deatha 13 (6.7) 9 (4.6)
Investigator decision 20 (10.3) 13 (6.6)
Duration of treatment, years
(randomized therapy)b
˃0 to 1 36 (18.5) 191 (97.4)
>1 to 2 25 (12.8) 0
>2 to 3 31 (15.9) 0
>3 to 4 24 (12.3) 0
>4 to 5 22 (11.3) 0
>5 to 6 57 (29.2) 0
aThese cases of death included the following: ibrutinib arm, pneumonia (n = 3),
sepsis (n = 2), unknown cause (sudden death, n = 2), neutropenic sepsis,
terminal bowel cancer, lung infection, cardiac arrest, subdural hematoma, and
burns and ensuing complications in one patient each; ofatumumab arm,
pneumonia (n = 2), upper respiratory tract infection, squamous cell carcinoma
of the neck, influenza A, aggressive squamous cell carcinoma of the scalp,
nocardiosis, fever of unknown origin, and bacteremia in one patient each.
bPlanned duration of treatment with ofatumumab was up to 24 weeks.
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41 months (range: 0.2-71.1), with 41% of patients receiving more than
four years of therapy (Table 1). Among patients initially assigned to
ibrutinib, 43/195 (22%) remained on therapy until study closure (Table 1
and Figure S1). The most common reasons for ibrutinib discontinuation
prior to study closurewere PD (72/195, 37%) andAEs (32/195, 16%). Pro-
gressive disease was evidenced as Richter's transformation in 20 patients
(10%) in the ibrutinib arm, occurring in eight, four, six, zero, and two
patients in years zero to one, one to two, two to three, three to four, and
for to five, respectively.
Median follow-up of the 196 patients initially assigned to the
ofatumumab arm was 65.6 months (range: 0.1-73.9) and median dura-
tion of ofatumumab treatment was 5.3 months (range: 0-9.0). In total,
133 of 196 patients (68%) crossed over to receive ibrutinib; 36% of
these patients (48/133) had received more than 4 years of next-line
ibrutinib therapy, and 35% (47/133) were still receiving ibrutinib at the
time of study closure. In addition, 15 of 196 patients (8%) had PD but
exited the study on or before the protocol amendment allowing for
crossover to receive ibrutinib.
3.2 | Progression-free survival
With an overall follow-up of 74 months, the median investigator
assessed PFS per IWCLL criteria was 44.1 months (95% confidence
interval [CI]: 38.5-56.2) in the ibrutinib arm and 8.1 months (95% CI:
7.8-8.3) in the ofatumumab arm. Similar to the prior analyses, PFS
was significantly longer for patients assigned to ibrutinib than for
patients assigned to ofatumumab (HR: 0.148; 95% CI: 0.113-0.196;
P˂.0001; Figure 1A). At the time of this analysis, 92% (180/196) of
patients initially assigned to ofatumumab had a PFS event. At the
60-month landmark, the estimated PFS rates were 40% in the
ibrutinib arm and 3% in the ofatumumab arm. Median PFS in patients
in the high-risk population (with del[17p], TP53 mutation, del[11q],
and/or unmutated IGHV status) was 44.1 months (95% CI: 38.5-56.9)
with ibrutinib and 8.0 months (95% CI: 6.4-8.2) with ofatumumab
(HR: 0.110; 95% CI: 0.080-0.152) (Figure 1B). The PFS benefit of
ibrutinib vs ofatumumab was consistent across subgroups defined by
patient baseline clinical and genomic risk factors; HRs ranged from
0.042 to 0.306 (Figure 1C).
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F IGURE 1 Progression-free survival (A) in the ITT population and (B) in the high-risk population (patientswith del(17p), TP53mutation, del(11q),
and/or unmutated IGHV status). (C) Forest plot of HRs for progression-free survival by baseline subgroups (ITT population). CI, confidence interval; ECOG,
Eastern CooperativeOncologyGroup; IGHV, immunoglobulin heavy-chain variable region gene; ITT, intention-to-treat; PFS, progression-free survival.
*Patientswith del(17p), TP53mutation, del(11q), and/or unmutated IGHV status
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Within the ibrutinib arm, median PFS by line of therapy was not
reached in patients who received 1 prior line of therapy (n = 35; 95% CI:
44.4-not estimable [NE]) and was 67.3 (n = 57; 95% CI: 36.0-NE), 44.1
(n = 32; 95% CI: 25.4-NE), 33.0 (n = 27; 95% CI: 13.6-NE), and
27.3 months (n = 44; 95% CI: 22.0-40.8) for patients who received two,
three, four, or five or more prior lines of therapy, respectively (Figure 2A).
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Purine analog refractoriness had no impact on PFS, with median PFS of
44.6 (n = 87; 95% CI: 31.7-57.4) and 44.0 months (n = 108; 95% CI:
35.1-60.7) in patients who were and were not refractory at study enroll-
ment, respectively (HR: 0.983; 95% CI: 0.685-1.413).
Median PFS was 40.6 months (95% CI: 25.4-44.6) in the del(17p)
subgroup (n = 63) and 60.7 months (95% CI: 36.4-NE) in the
del(11q) subgroup (n = 50; Figure 2B). Median PFS was 42.5 months
(95% CI: 31.7-56.2) in patients with neither del(11q) nor del(17p)
(n = 81). In an exploratory analysis that combined data from patients
with del(17p) and those with TP53 mutation, median PFS was
40.6 months (95% CI: 27.5-44.1) in the subgroup with del(17p)
and/or TP53 mutation (n = 104) and 56.9 months (95% CI: 27.5-NE)
in the del(11q) subgroup (n = 33) (Figure S2). Median PFS was not
reached (95% CI: 42.5-NE) in patients with neither del(11q) nor
del(17p)/TP53 mutation (n = 58). Patients with complex karyotype
(n = 39) had a median PFS of 40.8 months (95% CI: 24.4-67.7) and
patients without a complex karyotype (n = 114) had a median PFS of
44.6 months (95% CI: 37.9-61.0) (HR: 1.279; 95% CI: 0.801-2.044)
(Figure 2C). Patients with mutated (n = 36) and unmutated (n = 98)
IGHV had similar PFS (median 48.4 [95% CI: 35.6-60.8] vs 49.7 [95%
CI: 40.2-NE] months; HR: 1.208; 95% CI: 0.741-1.971) (Figure 2D).
Patients without TP53 mutation (n = 75) had a median PFS of
56.9 months (95% CI: 36.4-NE), longer than the median PFS of
40.7 months (95% CI: 25.4-44.6) for patients with TP53 mutations
(n = 79) (HR: 1.731; 95% CI: 1.156-2.593) (Figure 2E). Median PFS
was 40.6 months (95% CI: 17.6-56.2) for patients with both del(17p)
and TP53 mutation (n = 38), 40.7 months (95% CI: 25.4-57.3) for
those with either del(17p) or TP53 mutation (n = 48), and
56.9 months (95% CI: 36.4-NE) for those with neither del(17p) nor
TP53 mutation (n = 68; Figure 2F).
3.3 | Overall response
At extended follow-up, the cumulative ORR was 91% for ibrutinib.
The proportion of patients with a best response of CR/CRi increased
over time to 11% with current follow-up (Figure S3).
3.4 | Overall survival
With up to 6 years of post-randomization follow-up, median OS was
67.7 months (95% CI: 61.0-NE) in the ibrutinib arm and 65.1 months
(95% CI: 50.6-NE) in the ofatumumab arm, irrespective of the extensive
(68%) crossover to ibrutinib (HR: 0.810; 95% CI: 0.602-1.091)
(Figure S4A). To compare OS outcomes between treatment arms
accounting for the extensive crossover from ofatumumab to ibrutinib
treatment, OS was analyzed with censoring at time of crossover and was
better among patients initially assigned to ibrutinib than to ofatumumab
(HR: 0.639; 95% CI: 0.418-0.975) (Figure S4B). A sensitivity analysis of
OS adjusting for crossover based on the RPSFT method also showed
continued OS benefit with ibrutinib compared with ofatumumab (HR:
0.240; 95% CI: 0.105-0.550). In patients with del(17p), median OS was
61.8 months (95% CI: 38.7-NE) in the ibrutinib arm. Among patients in
the ibrutinib arm with PD in the first year of study (n = 19), median OS
was 13.5 months (95% CI: 6.7-26.6). Median OS in patients with PD dur-
ing the first two years (n = 33) was 26.0 months (95% CI: 13.6-32.4), and
in patients with PD at any time in the first four years (n = 72) was
39.3 months (95% CI: 34.2-50.8).
3.5 | Patient-reported outcomes
Patient-reported outcomes during long-term follow-up were evalu-
ated using FACIT-F and the EuroQol 5-Dimensions 5-Level (EQ-5D-
5L; © EuroQol Research Foundation. EQ-5D™ is a trade mark of the
EuroQol Research Foundation) questionnaires (Supplementary
Methods). The mean (standard deviation [SD]) FACIT-F score at baseline
was 36.2 (12.3) for the ibrutinib arm and 35.6 (11.9) for the ofatumumab
arm. A greater proportion of patients achieved clinically meaningful
improvement in FACIT-F score with ibrutinib (65%) than with
ofatumumab (49%; Figure S5A). At baseline, mean (SD) EQ-5D-5L visual
analog scale (VAS) scores were 66.5 (21.4) for ibrutinib and 67.6 (19.7)
for ofatumumab. Similarly, a greater proportion of patients achieved clini-
cally meaningful improvement in their EQ-5D-5L VAS Scores with
ibrutinib (66%), than with ofatumumab (45%). Improvements in the
FACIT-F score and the EQ-5D-5L VAS were largely maintained over
time with ibrutinib (Figures S5B, S5C).
3.6 | Adverse events
At final analysis, the most commonly reported treatment-emergent AEs
of any grade (occurring in ≥20% of the population) remained consistent
with previous reports of patients treated with ibrutinib (Figure S6) and
generally decreased over time for patients remaining on ibrutinib ther-
apy, with few exceptions (hypertension and bruising). Over up to
71 months of treatment, commonly reported grade ≥3 hematologic AEs
included neutropenia (25%), thrombocytopenia (10%), and anemia (9%).
Commonly reported grade ≥3 nonhematologic AEs included pneumonia
(21%), hypertension (9%), urinary tract infection (7%), diarrhea (7%), and
atrial fibrillation (6%). Overall, 19 patients (10%) in the ibrutinib arm
experienced major hemorrhage. The prevalence of any grade ≥3 AEs
with ibrutinib decreased after the first year and remained stable thereaf-
ter, with rates of 62%, 48%, 46%, 46%, 48%, and 32% during years zero
to one, one to two, two to three, three to four, four to five, and five to
six, respectively.
In line with the overall prevalence, the prevalence of most
grade ≥3 AEs of clinical interest with ibrutinib decreased over time
(Figure 3). With up to 6 years of follow-up, grade ≥3 infections
occurred in 87 patients (45%) in the ibrutinib arm (Figure S7), occur-
ring at a median time of onset of 7.0 months (range: 0.0 to 63.0). The
most frequent categories/types of grade ≥3 infections included pneu-
monia (21%), urinary tract infection (7%), cellulitis (4%), sepsis (4%),
and lung infection (4%). The prevalence of grade ≥3 atrial fibrillation
was 4%, 0%, 2%, 2%, 1%, and 0% over years zero to one, one to two,
two to three, three to four, four to five, and five to six, respectively
(Figure 3). The prevalence of all-grade atrial fibrillation was 6%, 5%,
8%, 8%, 6%, and 4% over years zero to one, one to two, two to three,
three to four, four to five, and five to six, respectively. Overall,
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24 patients (12%) experienced atrial fibrillation of any grade, with a
median duration of 10.0 days (range: 1-1323) for the events
(Table S2). Most patients who experienced atrial fibrillation had one
or more relevant risk factors (22/24, 92%), such as a history of cardio-
vascular disease (10/24, 42%), hypertension (9/24, 38%), and/or base-
line body mass index ˃25 kg/m2 (11/24, 46%). Most received
concomitant medications (19/24, 79%), including antithrombotic med-
ications in eight of 24 patients (33%). The prevalence of grade ≥3
hypertension was 4%, 8%, 7%, 7%, 8%, and 11% over years zero to
one, one to two, two to three, three to four, four to five, and five to
six, respectively (Figure 3). A total of 41 patients (21%) experienced
hypertension of any grade (Figure S8), occurring at a median time of
onset of 13.8 months (range: 1.0-54.0) and a median duration of
16.6 months (range: 0.1-64.5) for the events (Table S3). Most patients
who experienced hypertension had relevant risk factors (28/41, 68%)
of either a history of hypertension or related disorders (21/41, 51%)
or a history of other risk factors, such as diabetes mellitus, hyperlipid-
emia, renal disease, smoking, or thyroid disease (19/41, 46%). Most
patients who experienced hypertension were treated with concomi-
tant antihypertensive medication during the treatment-emergent
period (26/41, 63%). Other AEs of clinical interest with ibrutinib
included peripheral neuropathy (all grade: n = 26 [13%]; grade ≥3:
n = 1 [0.5%]), congestive heart failure (all grade: n = 9 [5%]; grade ≥3:
n = 5 [3%]), and ventricular arrhythmia (all grade: n = 2 [1%]; no
grade ≥3 events).
Among patients in the ibrutinib arm, 17% (34/195) and 65%
(126/195) of patients required dose reductions and dose holds,
respectively, to manage AEs. Among the 34 patients with dose reduc-
tions due to AEs, eight (24%) ultimately discontinued because of an
AE, of which 4 discontinuations (12%) were due to the same AE that
led to dose reduction. Of the 126 patients with a dose held because
of AEs, 20 patients (16%) ultimately discontinued ibrutinib because of
an AE, of which 13 discontinuations (10%) were due to the same AE
that led to the dose hold. The frequency of AEs that led to ibrutinib
discontinuation remained consistent over time, and occurred in 6%,
3%, 4%, 4%, 6%, and 4% of patients during years zero to one, one to
two, two to three, three to four, four to five, and five to six, respec-
tively. Over the course of follow-up with a median treatment duration
of 41 months, 32 of 195 patients (16%) discontinued ibrutinib due to
AEs, including 11 grade 5 events of sepsis (n = 3), pneumonia (n = 2),
unknown cause (sudden death, n = 2), lower respiratory tract infection
(n = 1), lung infection (n = 1), cardiac arrest (n = 1), terminal bowel can-
cer (n = 1), subdural hematoma (n = 1), and serious burn and ensuing
complications (n = 1).
3.7 | Response to next-line treatment following
ibrutinib discontinuation
Best response to next-line CLL therapy was reported for 27 patients
after discontinuation of ibrutinib randomized therapy. Reasons for dis-
continuation in these patients included PD (n = 22), AE (n = 3), and
investigator decision (n = 2). Responses were observed in 10 of these
27 patients upon next-line treatment, including patients who had dis-
continued ibrutinib due to PD (eight of 22), AE (one of three), and
physician decision (one of two). Next-line treatment regimens with
responders were venetoclax single agent (five responders of seven
treated), idelalisib + rituximab (two of six), high-dose methylpredniso-
lone + monoclonal antibody (one of one, alemtuzumab), and investiga-
tional agent(s) (two of three).
4 | DISCUSSION
Targeted therapy with ibrutinib for relapsed CLL has changed the nat-
ural history of this disease, as first demonstrated in the trial described
herein. This 6-year update of the RESONATE study confirmed the
robust efficacy of ibrutinib in patients with relapsed or refractory CLL.
The median PFS of 44.1 months in the ibrutinib arm is substantially
superior to the median PFS in the comparator arm of ofatumumab
(8.1 months) and to that of other treatments available at the time of
study initiation. The efficacy of ibrutinib is confirmed in patients with
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F IGURE 3 Prevalence of grade ≥3 AEs of clinical interest over
time for ibrutinib arm (ITT population). Prevalence was determined by
the proportion of patients with a given AE (existing event or new
onset of an event) during each yearly interval. Multiple onsets of the
same AE term within a specific yearly interval were counted once, and
the same AE term continuing across several yearly intervals was
counted in each of the intervals. Congestive heart failure and
peripheral neuropathy were defined per terms included in the SMQ
(narrow). Major hemorrhage (combined terms) was defined as any
hemorrhagic event grade ≥3 in severity, or that results in one of the
following: intraocular bleeding causing vision loss, need for a
transfusion of ≥2 units of RBC or equivalent, hospitalization, or
prolongation of hospitalization. Infections (combined terms) include
AEs reported under “infections and infestations” system organ class
category. AE, adverse event; ITT, intention-to-treat; RBC, red
blood cells
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high-risk clinical and genomic features, including TP53 alteration (dele-
tion/mutation), unmutated IGHV status, complex karyotype, and ATM
aberrations (as shown by del[11q]). Analysis of OS is confounded by
the high number of patients (n = 133) who crossed over to receive
ibrutinib, with nonprogressing ofatumumab arm patients having the
most indolent disease, and with ibrutinib use prolonging survival of
the patients who crossed over. Despite this, when censored for cross-
over, OS was significantly improved in patients treated with ibrutinib
although the difference in the median OS for ibrutinib vs ofatumumab
was small (2.6 months). While a larger difference was observed using
the RPSFT method, the analysis was confounded by the design of the
study, which permitted early and extensive crossover, and the under-
lying assumption of this method that there is a constant risk of death
throughout the study for both treatment arms. As expected, analysis
of OS outcomes by timing of relapse suggests that patients who expe-
rienced PD earlier in the course of ibrutinib treatment (within the first
one or two years) had shorter OS, as compared to those who experi-
enced PD at any time in the first four years. Ibrutinib was well toler-
ated; the main reason for treatment discontinuation in this extended
follow-up was PD rather than drug-related toxicity. The frequency
and timing of Richter's transformation in ibrutinib-treated patients in
the RESONATE study are consistent with emerging data from clinical
studies with novel agents and historical data with chemotherapy-
based regimens.20-27 Notably, the patient population in the RESO-
NATE study was characterized by a high prevalence of factors previ-
ously identified as associated with increased risk of Richter's
transformation, including genomic risk factors and heavy prior treat-
ment burden. Most cases of Richter's transformation were identified
early in the course of ibrutinib treatment, with almost half of cases
occurring in the first year and all but two of the remaining cases
occurring during years 2 and 3.
Studies have shown that patients with del(17p) CLL treated
with standard chemoimmunotherapy regimens have poor out-
comes.7,12,28-30 The 5-year follow-up data from the relapsed/
refractory cohort of the phase 2 PCYC-1102/1103 study with
single-agent ibrutinib showed a lower PFS rate in patients with
del(17p) than in patients without del(17p).31 The 3-year follow-up
of the RESONATE study reported the effectiveness of ibrutinib in
patients regardless of del(17p).19 In this final analysis of RESO-
NATE with 6 years of follow-up, we confirm no significant differ-
ence in PFS for ibrutinib-treated patients with or without del(17p).
However, when data from patients with TP53 mutation were
pooled with those with del(17p) in an exploratory analysis, we
observed a lower PFS rate in the subgroup of patients with del(17p)
and/or TP53 mutation than in patients without either of these
abnormalities. Consistent with findings reported with earlier RESO-
NATE follow-up,32 the subset of ibrutinib-treated patients with
both del(17p) and TP53 mutation trended to have shorter PFS rela-
tive to patients without either of these high-risk features. In con-
trast to the earlier report from RESONATE, PFS outcomes in
patients with either del(17p) or TP53 mutation (but not both) were
similar to that of patients with both del(17p) and TP53 mutation.
The small number of patients in these subgroups and the
retrospective genetic/molecular analysis defining many of the sub-
groups may be potential limitations in the interpretation of these
results. Development of acquired mutations in the B-cell receptor
signaling pathway has been observed in patients relapsing during
ibrutinib treatment and together with other as yet undefined mech-
anisms contributing to relapse may be associated with unstable
genomes. Answers to these questions are being actively pursued in
ongoing studies.
Unmutated IGHV and del(11q) have an adverse prognostic impact
on patients with CLL.2-5 The negative impact from these markers has
been substantially abrogated in the context of ibrutinib therapy, as
shown in this study and other studies.28,33 This is confirmed by the
current results from RESONATE in which patients with del(11q) CLL
appeared to have no decrement in benefit from continuous ibrutinib
therapy. This is reflected in the median PFS for this group (n = 50),
which was 60.7 months and appeared to be longer than the median
PFS of the overall ibrutinib cohort. In addition, median PFS with
ibrutinib treatment was similar between patients with mutated and
unmutated IGHV. Thus, our follow-up data suggest that IGHV muta-
tional status and del(11q) have no impact on the long-term outcomes
with ibrutinib treatment.
The ORR with ibrutinib remains high with longer follow-up (91%)
and was similar to rates reported with a median follow-up of
44 months (91%).19 The CR/CRi rates have increased over time with
ibrutinib treatment, approaching a plateau beyond 3.5 years (9% and
11% with median 44 and 64 months of follow-up, respectively). This
is consistent with deepening of response with continuous ibrutinib
therapy for responding patients and is similar to the improved
responses observed over time with longer follow-up in patients with
relapsed/refractory CLL in the HELIOS study and in the phase
2 PCYC-1102/1103 study.31,34 Notably, the proportion of patients
who reported clinically meaningful improvement in FACIT-F score
was greater with ibrutinib than ofatumumab, and the improvement
was maintained over time.
Assessment of long-term safety data is an important factor with
continuous therapy, especially given the extended progression-free
efficacy conferred by ibrutinib treatment. This update confirms that
ibrutinib is well tolerated, and the prevalence of most grade ≥3 AEs of
clinical interest decreased with each subsequent year of treatment,
apart from hypertension, in which prevalence remained relatively con-
sistent from year to year. During prolonged follow-up, the overall
prevalence of treatment-emergent atrial fibrillation and hypertension
of any grade were 12% and 21%, respectively. These rates were simi-
lar to those reported earlier in RESONATE with a median 44-month
follow-up (11% and 20%, respectively). In addition, most of the
patients who developed atrial fibrillation or hypertension had relevant
risk factors for developing these complications.35-37 It is important to
note that the incidence of major hemorrhage with continued treat-
ment was consistently low over the extended follow-up period. In
addition, substantial proportions of ibrutinib-treated patients who
experienced dose reductions or dose holds due to AEs were able to
restart or remain on ibrutinib treatment (15% and 25% of these
patients, respectively, remained on ibrutinib until study closure). There
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were no new or concerning AE trends or unexpected events noted
with extended follow-up, and the safety profile appears consistent
with earlier reports.
To conclude, these 6-year follow-up results from the RESONATE
study confirm the robust and durable efficacy of ibrutinib with
extended treatment in patients with relapsed or refractory CLL. The
improvement in outcomes is evident in all risk groups, including
patients with high-risk clinical and genomic features, and the safety
analyses established that continuous treatment with ibrutinib can be
delivered long-term to provide benefit to patients with CLL.
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